Completed PHASE3 INTERVENTIONAL 1-arm NCT00426660

Expanded Access Program for Maraviroc At Multiple Centers

A Multicenter, Open Label, Expanded Access Trial Of Maraviroc

Sponsor: ViiV Healthcare

Interventions maraviroc

Updated 8 times since 2017 Last updated: May 23, 2016 Started: Feb 28, 2007 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates HIV Infections and is currently completed. ViiV Healthcare leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ViiV Healthcare

Data source: ViiV Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A-1090, Austria , Adelaide, Australia , Albany, United States , Alicante, Spain , Allentown, United States , Annandale, United States , Antwerp, Belgium , Arlington, United States , Athens, Greece , Atlanta, United States and 225 more locations